23 Mar 2026 • India’s pharmaceutical market is undergoing a major shift following the expiration of semaglutide’s patent, the active ingredient in blockbuster drugs like Ozempic and Wegovy. Within days, leading domestic players- including Dr. Reddy’s Laboratories, Sun Pharmaceutical Industries, and Zydus Lifesciences - launched significantly lower-priced versions, cutting treatment costs by 50–90%.

This rapid rollout marks the beginning of what analysts describe as a full-scale generic surge, with over 40 companies expected to introduce more than 50 semaglutide variants.

The move dramatically improves access to GLP-1 receptor agonists, which have seen explosive global demand for both Type 2 diabetes and obesity management but have remained cost-prohibitive for many patients.

India’s anti-obesity drug market has already expanded sharply, from about $16 million in 2021 to nearly $100 million, fueled in part by the earlier launch of Rybelsus, the oral form of semaglutide. The entry of low-cost generics is expected to accelerate this growth further, transforming GLP-1 therapy from a premium niche into a mass-access treatment category.

Beyond domestic impact, Indian manufacturers are positioning themselves for global expansion, targeting emerging markets such as Latin America and parts of Asia where affordability remains a major barrier. This development signals a pivotal inflection point in diabetes and obesity care, with India poised to reshape pricing dynamics, and potentially access, across the global GLP-1 landscape.